BioMarin to acquire Amicus in all-cash deal with equity value of $4.8 bn
MLex Summary: San Rafael, California-based BioMarin Pharmaceutical has agreed to acquire Princeton, New Jersey-based Amicus Therapeutics in an all-cash deal with an equity value of $4.8 billion. The merger is expected to...To view the full article, register now.
Already a subscriber? Click here to view full article